Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASCHIX:ALKBC 93 3-Year EPS without NRI Growth Rate is 52.90% as of Jun. 2026, which is 6% above its 10-year median of 49.80. GuruFocus rates CHIX:ALKBC with a GF Score™ of 93/100 and a GF Value™ of kr227.43 (Fairly Valued). Among 1,160 Biotechnology companies, Alk-Abello AS ranks better than 86.55% on this metric.
During the past 12 months, Alk-Abello AS's average EPS without NRI Growth Rate was 33.20% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 52.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 96.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Alk-Abello AS was 168.20% per year. The lowest was -20.90% per year. And the median was 49.80% per year.
Alk-Abello AS (CHIX:ALKBc) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Alk-Abello AS 3-Year EPS without NRI Growth Rate Related Terms
CHIX:ALKBC vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Alk-Abello AS's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's 3-Year EPS without NRI Growth Rate falls into.
Alk-Abello AS 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 52.90% mean?
Alk-Abello AS (CHIX:ALKBC) has a 3-Year EPS without NRI Growth Rate of 52.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Alk-Abello AS and its competitors. This is near median its historical median of 49.80. According to the industry distribution chart, Alk-Abello AS ranks #156 out of 1160 companies in the Biotechnology industry, placing it in the top 13.4%.
Is Alk-Abello AS's 3-Year EPS without NRI Growth Rate too high?
Alk-Abello AS's current 3-Year EPS without NRI Growth Rate of 52.90% is near median its 10-year median of 49.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.95. Alk-Abello AS's value of 52.90% is 231.7% above this industry median. Based on the distribution chart, Alk-Abello AS ranks #156 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alk-Abello AS has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #156 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Alk-Abello AS in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 15.95. Alk-Abello AS's value of 52.90% is 231.7% above this benchmark. While the company's 10-year median is 49.80 vs. the industry median of 15.95, Alk-Abello AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current 3-Year EPS without NRI Growth Rate of 52.90% is 231.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Alk-Abello AS and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current 3-Year EPS without NRI Growth Rate is 52.90%, which is near median its own 10-year median of 49.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Fairly Valued. The stock's GF Value™ is kr227.43, compared to a current price of kr221.50 — trading 2.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 52.90%, which is near median its 10-year median of 49.80 and 231.7% above the Biotechnology industry median of 15.95. Alk-Abello AS's overall GF Score™ is 93/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current 3-Year EPS without NRI Growth Rate is 52.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be undervalued.
The current stock price of kr221.50 is trading 2.6% below its estimated GF Value™ of kr227.43.
GuruFocus considers Alk-Abello AS to be Fairly Valued.
Key valuation signals for CHIX:ALKBC:
3-Year EPS without NRI Growth Rate: 52.90% (near median its 10-year median of 49.80)
GF Value™: kr227.43 vs. price of kr221.50 (2.6% below fair value)
Industry Position: 231.7% above the Biotechnology median (#156 of 1160)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
93GF Score
Get the complete analysis for CHIX:ALKBC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
